Technology
Health
Biotechnology
Onconova Therapeutics
$4.169876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$4.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ONTX and other stocks, options, ETFs, and crypto commission-free!
About
Onconova Therapeutics, Inc. Common Stock, also called Onconova Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. Read More It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
Employees
25
Headquarters
Newtown, Pennsylvania
Founded
1998
Market Cap
23.60M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
123.92K
High Today
$4.23
Low Today
$4.02
Open Price
$4.19
Volume
49.87K
52 Week High
$15.75
52 Week Low
$1.69
Collections
Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
News
Associated PressMar 12
Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
NEWTOWN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will participate in the 31st Annual ROTH Conference to be held March 17-19, 2019 at the Ritz Carlton Laguna Niguel in Orange County, CA. Steven M. Fruchtman, MD, President & CEO, and Mark Guerin, CFO, will attend the confe...
Price Paid on Robinhood
44% Lower
Right Now
52 Week Low
$1.69
Average Price Paid
$7.38
52 Week High
$15.75
Earnings
-$1.16
-$0.80
-$0.43
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.87 per share
Actual
Available Mar 26, Pre-Market